WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013125675) COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/125675 International Application No.: PCT/JP2013/054488
Publication Date: 29.08.2013 International Filing Date: 22.02.2013
IPC:
G01N 33/68 (2006.01) ,A61K 31/282 (2006.01) ,A61K 31/513 (2006.01) ,A61K 45/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 43/00 (2006.01) ,G01N 33/15 (2006.01) ,G01N 33/50 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
28
Compounds containing heavy metals
282
Platinum compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
15
Medicinal preparations
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Applicants: KEIO UNIVERSITY[JP/JP]; 15-45, Mita 2-chome, Minato-ku, Tokyo 1088345, JP
KABUSHIKI KAISHA YAKULT HONSHA[JP/JP]; 1-19, Higashi Shinbashi 1-chome, Minato-ku, Tokyo 1058660, JP
Inventors: TANIGAWARA, Yusuke; JP
NISHIMUTA, Akito; JP
TSUZAKI, Junya; JP
TAKAHASHI, Hiroyuki; JP
Agent: THE PATENT CORPORATE BODY ARUGA PATENT OFFICE; Sawanotsuru Ningyocho Bldg., 1-3-8, Nihonbashi Ningyocho, Chuo-ku, Tokyo 1030013, JP
Priority Data:
2012-03744823.02.2012JP
Title (EN) COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER
(FR) MARQUEUR DÉTERMINANT LA SENSIBILITÉ À DES MÉDICAMENTS ANTICANCÉREUX COMBINÉS
(JA) 併用抗がん剤の感受性判定マーカー
Abstract:
(EN) Provided are an anticancer sensitivity-determining marker by which responsiveness to treatment of individual patients can be discriminated and a novel cancer treatment means using the same. A marker for determining the sensitivity to an anticancer drug including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, comprises at least one molecule selected from an amino acid metabolic substance, a nucleic acid metabolic substance, a pentose phosphate pathway substance, a glycolysis substance, a TCA cycle substance, a polyamine metabolic substance, and substances involved in the metabolic system associated with 7,8-Dihydrobiopterin, 6-Phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+ and molecules thereof.
(FR) L'invention concerne un marqueur déterminant la sensibilité aux anticancéreux, au moyen duquel la réactivité au traitement de patients individuels peut être discernée, ainsi qu'un moyen inédit de traitement du cancer l'utilisant. Un marqueur servant à déterminer la sensibilité à un médicament anticancéreux, comprenant de l'oxaliplatine ou un sel de celle-ci et du fluorouracil ou un sel de celui-ci, comporte au moins une molécule choisie parmi une substance métabolique d'acide aminé, une substance métabolique d'acide nucléique, une substance de la voie des pentoses phosphates, une substance de glycolyse, une substance de cycle de TCA, une substance métabolique de polyamine et des substances impliquées dans le système métabolique associé à la 7,8- dihydrobioptérine, à l'acide 6-phosphogluconique, à l'acide butyrique, à la triéthanolamine, au 1-méthylnicotinamide, au NADH, au NAD+ et à leurs molécules.
(JA)  個々の患者の治療反応性を判別できる抗がん剤感受性判定マーカー及びそれを利用する新たながん治療手段を提供する。 アミノ酸代謝系上の物質、核酸代謝系上の物質、ペントースリン酸経路上の物質、解糖系上の物質、TCA回路上の物質、ポリアミン代謝系上の物質並びに7,8-Dihydrobiopterin、6-Phosphogluconic acid、Butyric acid、Triethanolamine、1-Methylnicotinamide、NADH、NAD及びそれら分子が関与する代謝系上の物質から選ばれる1以上の分子からなる、オキサリプラチン又はその塩とフルオロウラシル又はその塩を含む抗がん剤の感受性判定マーカー。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)